ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Engineered Xenogeneic Bone Scaffold with IL-10 Nanodelivery System: Immunomodulation and BMSC Fate Programming for Skull Defect Repair.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineered Xenogeneic Bone Scaffold with IL-10 Nanodelivery System: Immunomodulation and BMSC Fate Programming for Skull Defect Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Skull defect reconstruction remains clinically challenging because current artificial implants lack bioactivity and produce radiological artifacts, whereas autologous bone grafts suffer from unpredictable resorption and infection. Here, we developed a multifunctional composite integrating antigen-extracted xenogeneic scaffold, IL-10-loaded mesoporous polydopamine nanoparticles (MPDA@IL-10), and autologous bone marrow-derived mesenchymal stem cells (BMSCs). The composite establishes a temporally phased immunoregulatory axis: nanoparticle-delivered exogenous IL-10 compresses the early inflammatory window, and BMSCs then secrete endogenous anti-inflammatory factors that prevent scaffold resorption and maintain a pro-regenerative milieu. Beyond immunomodulation, IL-10 acts as a lineage-determining cue, activating PI3K-Akt/Wnt signaling to drive BMSC osteogenic commitment and suppress adipogenic drift at the early differentiation stage. In a canine critical-sized skull defect model, this strategy markedly enhanced radiographic and histological regeneration. By uniting temporal immune modulation with stem cell fate programming, this approach offers a translatable route to skull repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.